Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FREEDOM-3S: Switching from Liraglutide to ITCA 650 in Type 2 Diabetes
NCT02638805Phase 3Completed
- Sponsor
- Intarcia Therapeutics
- Start
- Dec 2015
- Primary completion
- Oct 2017
- Countries
- 1
01
Overview
A Phase 3 trial of ITCA 650 in type 2 diabetes mellitus (T2DM), sponsored by Intarcia Therapeutics. Started Dec 2015; status: completed.
02
Drugs
ITCA 650
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02638805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02638805.